ImmunityBio Sees ANKTIVA Revenue Soar 700% to $113M with 750% Unit Sales Gain
ImmunityBio's net product revenue for ANKTIVA jumped 700% to $113 million in 2025, driven by a 750% increase in unit sales. The company narrowed its net loss to $351.4 million and secured regulatory approvals in 33 countries, including a second metastatic lung cancer indication in Saudi Arabia.
1. ANKTIVA Revenue and Volume Growth
ImmunityBio's ANKTIVA net product revenue soared 700% year-over-year to $113 million in 2025, propelled by a 750% increase in unit sales and 20% sequential growth in Q4, underscoring rapid clinical adoption of its lead immunotherapy.
2. Financial Performance
The company narrowed its net loss to $351.4 million, down from 2024 levels, as administrative expenses declined, although research and development spending increased to $218.6 million to support an expanding clinical pipeline.
3. Global Approvals and Partnerships
ImmunityBio secured regulatory authorizations for ANKTIVA in 33 countries across the US, UK, EU and Saudi Arabia; the Saudi authority approved a second metastatic non-small cell lung cancer indication, and partnerships were formed with Accord Healthcare and BioPharma & Cigalah.
4. Strategic Outlook
The firm launched a three-year global strategy positioning ANKTIVA as the backbone of its Cancer BioShield platform targeting glioblastoma, pancreatic cancer and lymphoma, supported by new subsidiaries in Dublin and Riyadh to drive international commercialization.